Research Progress in Circulating Tumor Cells of Glioblastoma
Glioblastoma(GBM) is a highly malignant tumor. Despite various treatment modalities, such as surgery, radiotherapy and chemotherapy, most patients with GBM are still dying of its recurrence. The prognosis of patients with GBM is extremely poor, which is related to not only tumor cell invasion and pr...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
TAN Hu [verfasserIn] LIU Chang [verfasserIn] ZHANG Qingmei [verfasserIn] XIAO Shaowen [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Chinesisch |
| Erschienen: |
2018 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Zhongliu Fangzhi Yanjiu - Magazine House of Cancer Research on Prevention and Treatment, 2019, 45(2018), 12, Seite 1020-1022 |
|---|---|
| Übergeordnetes Werk: |
volume:45 ; year:2018 ; number:12 ; pages:1020-1022 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.3971/j.issn.1000-8578.2018.18.0603 |
|---|
| Katalog-ID: |
DOAJ010468110 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ010468110 | ||
| 003 | DE-627 | ||
| 005 | 20230503142659.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2018 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3971/j.issn.1000-8578.2018.18.0603 |2 doi | |
| 035 | |a (DE-627)DOAJ010468110 | ||
| 035 | |a (DE-599)DOAJ32a9a9c9e4ff43ab8e917c97c98856b3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a TAN Hu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Research Progress in Circulating Tumor Cells of Glioblastoma |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Glioblastoma(GBM) is a highly malignant tumor. Despite various treatment modalities, such as surgery, radiotherapy and chemotherapy, most patients with GBM are still dying of its recurrence. The prognosis of patients with GBM is extremely poor, which is related to not only tumor cell invasion and proliferation, but also immature tumor monitoring methods. For a long time, many studies have found that circulating tumor cells(CTCs) can be detected in patients' blood. It plays an extremely important role in the recurrence of GBM. Therefore, the CTCs detection technology of glioblastoma and its clinical significance have been a hotspot in the present research. | ||
| 650 | 4 | |a glioblastoma | |
| 650 | 4 | |a circular marker | |
| 650 | 4 | |a circulating tumor cells | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 700 | 0 | |a LIU Chang |e verfasserin |4 aut | |
| 700 | 0 | |a ZHANG Qingmei |e verfasserin |4 aut | |
| 700 | 0 | |a XIAO Shaowen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Zhongliu Fangzhi Yanjiu |d Magazine House of Cancer Research on Prevention and Treatment, 2019 |g 45(2018), 12, Seite 1020-1022 |w (DE-627)176063638X |x 10008578 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2018 |g number:12 |g pages:1020-1022 |
| 856 | 4 | 0 | |u https://doi.org/10.3971/j.issn.1000-8578.2018.18.0603 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/32a9a9c9e4ff43ab8e917c97c98856b3 |z kostenfrei |
| 856 | 4 | 0 | |u http://html.rhhz.net/ZLFZYJ/html/8578.2018.18.0603.htm |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1000-8578 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1000-8578 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2018 |e 12 |h 1020-1022 | ||
| author_variant |
t h th l c lc z q zq x s xs |
|---|---|
| matchkey_str |
article:10008578:2018----::eerhrgesnicltntmrel |
| hierarchy_sort_str |
2018 |
| callnumber-subject-code |
RC |
| publishDate |
2018 |
| allfields |
10.3971/j.issn.1000-8578.2018.18.0603 doi (DE-627)DOAJ010468110 (DE-599)DOAJ32a9a9c9e4ff43ab8e917c97c98856b3 DE-627 ger DE-627 rakwb chi RC254-282 TAN Hu verfasserin aut Research Progress in Circulating Tumor Cells of Glioblastoma 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Glioblastoma(GBM) is a highly malignant tumor. Despite various treatment modalities, such as surgery, radiotherapy and chemotherapy, most patients with GBM are still dying of its recurrence. The prognosis of patients with GBM is extremely poor, which is related to not only tumor cell invasion and proliferation, but also immature tumor monitoring methods. For a long time, many studies have found that circulating tumor cells(CTCs) can be detected in patients' blood. It plays an extremely important role in the recurrence of GBM. Therefore, the CTCs detection technology of glioblastoma and its clinical significance have been a hotspot in the present research. glioblastoma circular marker circulating tumor cells Neoplasms. Tumors. Oncology. Including cancer and carcinogens LIU Chang verfasserin aut ZHANG Qingmei verfasserin aut XIAO Shaowen verfasserin aut In Zhongliu Fangzhi Yanjiu Magazine House of Cancer Research on Prevention and Treatment, 2019 45(2018), 12, Seite 1020-1022 (DE-627)176063638X 10008578 nnns volume:45 year:2018 number:12 pages:1020-1022 https://doi.org/10.3971/j.issn.1000-8578.2018.18.0603 kostenfrei https://doaj.org/article/32a9a9c9e4ff43ab8e917c97c98856b3 kostenfrei http://html.rhhz.net/ZLFZYJ/html/8578.2018.18.0603.htm kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 45 2018 12 1020-1022 |
| spelling |
10.3971/j.issn.1000-8578.2018.18.0603 doi (DE-627)DOAJ010468110 (DE-599)DOAJ32a9a9c9e4ff43ab8e917c97c98856b3 DE-627 ger DE-627 rakwb chi RC254-282 TAN Hu verfasserin aut Research Progress in Circulating Tumor Cells of Glioblastoma 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Glioblastoma(GBM) is a highly malignant tumor. Despite various treatment modalities, such as surgery, radiotherapy and chemotherapy, most patients with GBM are still dying of its recurrence. The prognosis of patients with GBM is extremely poor, which is related to not only tumor cell invasion and proliferation, but also immature tumor monitoring methods. For a long time, many studies have found that circulating tumor cells(CTCs) can be detected in patients' blood. It plays an extremely important role in the recurrence of GBM. Therefore, the CTCs detection technology of glioblastoma and its clinical significance have been a hotspot in the present research. glioblastoma circular marker circulating tumor cells Neoplasms. Tumors. Oncology. Including cancer and carcinogens LIU Chang verfasserin aut ZHANG Qingmei verfasserin aut XIAO Shaowen verfasserin aut In Zhongliu Fangzhi Yanjiu Magazine House of Cancer Research on Prevention and Treatment, 2019 45(2018), 12, Seite 1020-1022 (DE-627)176063638X 10008578 nnns volume:45 year:2018 number:12 pages:1020-1022 https://doi.org/10.3971/j.issn.1000-8578.2018.18.0603 kostenfrei https://doaj.org/article/32a9a9c9e4ff43ab8e917c97c98856b3 kostenfrei http://html.rhhz.net/ZLFZYJ/html/8578.2018.18.0603.htm kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 45 2018 12 1020-1022 |
| allfields_unstemmed |
10.3971/j.issn.1000-8578.2018.18.0603 doi (DE-627)DOAJ010468110 (DE-599)DOAJ32a9a9c9e4ff43ab8e917c97c98856b3 DE-627 ger DE-627 rakwb chi RC254-282 TAN Hu verfasserin aut Research Progress in Circulating Tumor Cells of Glioblastoma 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Glioblastoma(GBM) is a highly malignant tumor. Despite various treatment modalities, such as surgery, radiotherapy and chemotherapy, most patients with GBM are still dying of its recurrence. The prognosis of patients with GBM is extremely poor, which is related to not only tumor cell invasion and proliferation, but also immature tumor monitoring methods. For a long time, many studies have found that circulating tumor cells(CTCs) can be detected in patients' blood. It plays an extremely important role in the recurrence of GBM. Therefore, the CTCs detection technology of glioblastoma and its clinical significance have been a hotspot in the present research. glioblastoma circular marker circulating tumor cells Neoplasms. Tumors. Oncology. Including cancer and carcinogens LIU Chang verfasserin aut ZHANG Qingmei verfasserin aut XIAO Shaowen verfasserin aut In Zhongliu Fangzhi Yanjiu Magazine House of Cancer Research on Prevention and Treatment, 2019 45(2018), 12, Seite 1020-1022 (DE-627)176063638X 10008578 nnns volume:45 year:2018 number:12 pages:1020-1022 https://doi.org/10.3971/j.issn.1000-8578.2018.18.0603 kostenfrei https://doaj.org/article/32a9a9c9e4ff43ab8e917c97c98856b3 kostenfrei http://html.rhhz.net/ZLFZYJ/html/8578.2018.18.0603.htm kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 45 2018 12 1020-1022 |
| allfieldsGer |
10.3971/j.issn.1000-8578.2018.18.0603 doi (DE-627)DOAJ010468110 (DE-599)DOAJ32a9a9c9e4ff43ab8e917c97c98856b3 DE-627 ger DE-627 rakwb chi RC254-282 TAN Hu verfasserin aut Research Progress in Circulating Tumor Cells of Glioblastoma 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Glioblastoma(GBM) is a highly malignant tumor. Despite various treatment modalities, such as surgery, radiotherapy and chemotherapy, most patients with GBM are still dying of its recurrence. The prognosis of patients with GBM is extremely poor, which is related to not only tumor cell invasion and proliferation, but also immature tumor monitoring methods. For a long time, many studies have found that circulating tumor cells(CTCs) can be detected in patients' blood. It plays an extremely important role in the recurrence of GBM. Therefore, the CTCs detection technology of glioblastoma and its clinical significance have been a hotspot in the present research. glioblastoma circular marker circulating tumor cells Neoplasms. Tumors. Oncology. Including cancer and carcinogens LIU Chang verfasserin aut ZHANG Qingmei verfasserin aut XIAO Shaowen verfasserin aut In Zhongliu Fangzhi Yanjiu Magazine House of Cancer Research on Prevention and Treatment, 2019 45(2018), 12, Seite 1020-1022 (DE-627)176063638X 10008578 nnns volume:45 year:2018 number:12 pages:1020-1022 https://doi.org/10.3971/j.issn.1000-8578.2018.18.0603 kostenfrei https://doaj.org/article/32a9a9c9e4ff43ab8e917c97c98856b3 kostenfrei http://html.rhhz.net/ZLFZYJ/html/8578.2018.18.0603.htm kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 45 2018 12 1020-1022 |
| allfieldsSound |
10.3971/j.issn.1000-8578.2018.18.0603 doi (DE-627)DOAJ010468110 (DE-599)DOAJ32a9a9c9e4ff43ab8e917c97c98856b3 DE-627 ger DE-627 rakwb chi RC254-282 TAN Hu verfasserin aut Research Progress in Circulating Tumor Cells of Glioblastoma 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Glioblastoma(GBM) is a highly malignant tumor. Despite various treatment modalities, such as surgery, radiotherapy and chemotherapy, most patients with GBM are still dying of its recurrence. The prognosis of patients with GBM is extremely poor, which is related to not only tumor cell invasion and proliferation, but also immature tumor monitoring methods. For a long time, many studies have found that circulating tumor cells(CTCs) can be detected in patients' blood. It plays an extremely important role in the recurrence of GBM. Therefore, the CTCs detection technology of glioblastoma and its clinical significance have been a hotspot in the present research. glioblastoma circular marker circulating tumor cells Neoplasms. Tumors. Oncology. Including cancer and carcinogens LIU Chang verfasserin aut ZHANG Qingmei verfasserin aut XIAO Shaowen verfasserin aut In Zhongliu Fangzhi Yanjiu Magazine House of Cancer Research on Prevention and Treatment, 2019 45(2018), 12, Seite 1020-1022 (DE-627)176063638X 10008578 nnns volume:45 year:2018 number:12 pages:1020-1022 https://doi.org/10.3971/j.issn.1000-8578.2018.18.0603 kostenfrei https://doaj.org/article/32a9a9c9e4ff43ab8e917c97c98856b3 kostenfrei http://html.rhhz.net/ZLFZYJ/html/8578.2018.18.0603.htm kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 45 2018 12 1020-1022 |
| language |
Chinese |
| source |
In Zhongliu Fangzhi Yanjiu 45(2018), 12, Seite 1020-1022 volume:45 year:2018 number:12 pages:1020-1022 |
| sourceStr |
In Zhongliu Fangzhi Yanjiu 45(2018), 12, Seite 1020-1022 volume:45 year:2018 number:12 pages:1020-1022 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
glioblastoma circular marker circulating tumor cells Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| isfreeaccess_bool |
true |
| container_title |
Zhongliu Fangzhi Yanjiu |
| authorswithroles_txt_mv |
TAN Hu @@aut@@ LIU Chang @@aut@@ ZHANG Qingmei @@aut@@ XIAO Shaowen @@aut@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
176063638X |
| id |
DOAJ010468110 |
| language_de |
chinesisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ010468110</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503142659.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2018 xx |||||o 00| ||chi c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3971/j.issn.1000-8578.2018.18.0603</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ010468110</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ32a9a9c9e4ff43ab8e917c97c98856b3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">chi</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">TAN Hu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Research Progress in Circulating Tumor Cells of Glioblastoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Glioblastoma(GBM) is a highly malignant tumor. Despite various treatment modalities, such as surgery, radiotherapy and chemotherapy, most patients with GBM are still dying of its recurrence. The prognosis of patients with GBM is extremely poor, which is related to not only tumor cell invasion and proliferation, but also immature tumor monitoring methods. For a long time, many studies have found that circulating tumor cells(CTCs) can be detected in patients' blood. It plays an extremely important role in the recurrence of GBM. Therefore, the CTCs detection technology of glioblastoma and its clinical significance have been a hotspot in the present research.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">glioblastoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">circular marker</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">circulating tumor cells</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">LIU Chang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">ZHANG Qingmei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">XIAO Shaowen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Zhongliu Fangzhi Yanjiu</subfield><subfield code="d">Magazine House of Cancer Research on Prevention and Treatment, 2019</subfield><subfield code="g">45(2018), 12, Seite 1020-1022</subfield><subfield code="w">(DE-627)176063638X</subfield><subfield code="x">10008578</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:45</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:12</subfield><subfield code="g">pages:1020-1022</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3971/j.issn.1000-8578.2018.18.0603</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/32a9a9c9e4ff43ab8e917c97c98856b3</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://html.rhhz.net/ZLFZYJ/html/8578.2018.18.0603.htm</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1000-8578</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1000-8578</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">45</subfield><subfield code="j">2018</subfield><subfield code="e">12</subfield><subfield code="h">1020-1022</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
TAN Hu |
| spellingShingle |
TAN Hu misc RC254-282 misc glioblastoma misc circular marker misc circulating tumor cells misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Research Progress in Circulating Tumor Cells of Glioblastoma |
| authorStr |
TAN Hu |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)176063638X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RC254-282 |
| illustrated |
Not Illustrated |
| issn |
10008578 |
| topic_title |
RC254-282 Research Progress in Circulating Tumor Cells of Glioblastoma glioblastoma circular marker circulating tumor cells |
| topic |
misc RC254-282 misc glioblastoma misc circular marker misc circulating tumor cells misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_unstemmed |
misc RC254-282 misc glioblastoma misc circular marker misc circulating tumor cells misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_browse |
misc RC254-282 misc glioblastoma misc circular marker misc circulating tumor cells misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Zhongliu Fangzhi Yanjiu |
| hierarchy_parent_id |
176063638X |
| hierarchy_top_title |
Zhongliu Fangzhi Yanjiu |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)176063638X |
| title |
Research Progress in Circulating Tumor Cells of Glioblastoma |
| ctrlnum |
(DE-627)DOAJ010468110 (DE-599)DOAJ32a9a9c9e4ff43ab8e917c97c98856b3 |
| title_full |
Research Progress in Circulating Tumor Cells of Glioblastoma |
| author_sort |
TAN Hu |
| journal |
Zhongliu Fangzhi Yanjiu |
| journalStr |
Zhongliu Fangzhi Yanjiu |
| callnumber-first-code |
R |
| lang_code |
chi |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
txt |
| container_start_page |
1020 |
| author_browse |
TAN Hu LIU Chang ZHANG Qingmei XIAO Shaowen |
| container_volume |
45 |
| class |
RC254-282 |
| format_se |
Elektronische Aufsätze |
| author-letter |
TAN Hu |
| doi_str_mv |
10.3971/j.issn.1000-8578.2018.18.0603 |
| author2-role |
verfasserin |
| title_sort |
research progress in circulating tumor cells of glioblastoma |
| callnumber |
RC254-282 |
| title_auth |
Research Progress in Circulating Tumor Cells of Glioblastoma |
| abstract |
Glioblastoma(GBM) is a highly malignant tumor. Despite various treatment modalities, such as surgery, radiotherapy and chemotherapy, most patients with GBM are still dying of its recurrence. The prognosis of patients with GBM is extremely poor, which is related to not only tumor cell invasion and proliferation, but also immature tumor monitoring methods. For a long time, many studies have found that circulating tumor cells(CTCs) can be detected in patients' blood. It plays an extremely important role in the recurrence of GBM. Therefore, the CTCs detection technology of glioblastoma and its clinical significance have been a hotspot in the present research. |
| abstractGer |
Glioblastoma(GBM) is a highly malignant tumor. Despite various treatment modalities, such as surgery, radiotherapy and chemotherapy, most patients with GBM are still dying of its recurrence. The prognosis of patients with GBM is extremely poor, which is related to not only tumor cell invasion and proliferation, but also immature tumor monitoring methods. For a long time, many studies have found that circulating tumor cells(CTCs) can be detected in patients' blood. It plays an extremely important role in the recurrence of GBM. Therefore, the CTCs detection technology of glioblastoma and its clinical significance have been a hotspot in the present research. |
| abstract_unstemmed |
Glioblastoma(GBM) is a highly malignant tumor. Despite various treatment modalities, such as surgery, radiotherapy and chemotherapy, most patients with GBM are still dying of its recurrence. The prognosis of patients with GBM is extremely poor, which is related to not only tumor cell invasion and proliferation, but also immature tumor monitoring methods. For a long time, many studies have found that circulating tumor cells(CTCs) can be detected in patients' blood. It plays an extremely important role in the recurrence of GBM. Therefore, the CTCs detection technology of glioblastoma and its clinical significance have been a hotspot in the present research. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA |
| container_issue |
12 |
| title_short |
Research Progress in Circulating Tumor Cells of Glioblastoma |
| url |
https://doi.org/10.3971/j.issn.1000-8578.2018.18.0603 https://doaj.org/article/32a9a9c9e4ff43ab8e917c97c98856b3 http://html.rhhz.net/ZLFZYJ/html/8578.2018.18.0603.htm https://doaj.org/toc/1000-8578 |
| remote_bool |
true |
| author2 |
LIU Chang ZHANG Qingmei XIAO Shaowen |
| author2Str |
LIU Chang ZHANG Qingmei XIAO Shaowen |
| ppnlink |
176063638X |
| callnumber-subject |
RC - Internal Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.3971/j.issn.1000-8578.2018.18.0603 |
| callnumber-a |
RC254-282 |
| up_date |
2024-07-03T14:59:51.430Z |
| _version_ |
1803570424244600832 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ010468110</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503142659.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2018 xx |||||o 00| ||chi c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3971/j.issn.1000-8578.2018.18.0603</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ010468110</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ32a9a9c9e4ff43ab8e917c97c98856b3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">chi</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">TAN Hu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Research Progress in Circulating Tumor Cells of Glioblastoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Glioblastoma(GBM) is a highly malignant tumor. Despite various treatment modalities, such as surgery, radiotherapy and chemotherapy, most patients with GBM are still dying of its recurrence. The prognosis of patients with GBM is extremely poor, which is related to not only tumor cell invasion and proliferation, but also immature tumor monitoring methods. For a long time, many studies have found that circulating tumor cells(CTCs) can be detected in patients' blood. It plays an extremely important role in the recurrence of GBM. Therefore, the CTCs detection technology of glioblastoma and its clinical significance have been a hotspot in the present research.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">glioblastoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">circular marker</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">circulating tumor cells</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">LIU Chang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">ZHANG Qingmei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">XIAO Shaowen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Zhongliu Fangzhi Yanjiu</subfield><subfield code="d">Magazine House of Cancer Research on Prevention and Treatment, 2019</subfield><subfield code="g">45(2018), 12, Seite 1020-1022</subfield><subfield code="w">(DE-627)176063638X</subfield><subfield code="x">10008578</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:45</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:12</subfield><subfield code="g">pages:1020-1022</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3971/j.issn.1000-8578.2018.18.0603</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/32a9a9c9e4ff43ab8e917c97c98856b3</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://html.rhhz.net/ZLFZYJ/html/8578.2018.18.0603.htm</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1000-8578</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1000-8578</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">45</subfield><subfield code="j">2018</subfield><subfield code="e">12</subfield><subfield code="h">1020-1022</subfield></datafield></record></collection>
|
| score |
7.4001417 |